Format

Send to

Choose Destination
Clin Imaging. 2013 Jan-Feb;37(1):41-9. doi: 10.1016/j.clinimag.2012.02.016. Epub 2012 Jun 8.

MRI perfusion in determining pseudoprogression in patients with glioblastoma.

Author information

1
Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. youngr@mskcc.org

Abstract

We examine the role of dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) perfusion in differentiating pseudoprogression from progression in 20 consecutive patients with treated glioblastoma. MRI perfusion was performed, and relative cerebral blood volume (rCBV), relative peak height (rPH), and percent signal recovery (PSR) were measured. Pseudoprogression demonstrated lower median rCBV (P=.009) and rPH (P<.001), and higher PSR (P=.039) than progression. DSC MRI perfusion successfully identified pseudoprogression in patients who did not require a change in treatment despite radiographic worsening following chemoradiotherapy.

PMID:
23151413
PMCID:
PMC4755513
DOI:
10.1016/j.clinimag.2012.02.016
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center